In fact, the possible involvement of cytotoxic Eomes+CD4+ T cells in SPMS hints at a potential reason why current immunomodulatory therapies aimed at conventional pathogenic cells proved ineffective for SPMS45. This evidence concerns the gene CD4 and secondary progressive multiple sclerosis.